Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 6/20 | 0.48 |
| ▸ | METAP2 | P50579 | 3/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | ICMT | O60725 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24143743 | 0.90 | NR1D1 (0.50) | NR1D1METAP2AAK1HTR2ACHEK1 | |
| SCHEMBL24143870 | 0.87 | NR1D1 (0.46) | NR1D1METAP2AAK1HTR2ACHEK1 | |
| SCHEMBL24143542 | 0.87 | NR1D1 (0.53) | NR1D1AAK1HTR2A | |
| SCHEMBL24143664 | 0.84 | NR1D1 (0.44) | NR1D1METAP2AAK1HTR2ACHEK1 | |
| SCHEMBL24142882 | 0.84 | HTR6 (0.44) | NR1D1HTR2AHTR6 | |
| SCHEMBL24143036 | 0.84 | HTR2A (0.54) | NR1D1METAP2AAK1HTR2ACHEK1 | |
| SCHEMBL24142979 | 0.84 | NR1D1 (0.67) | NR1D1ICMT | |
| SCHEMBL24144346 | 0.84 | NR1D1 (0.44) | NR1D1METAP2AAK1HTR2ACHEK1 | |
| SCHEMBL24144078 | 0.81 | NR1D1 (0.48) | NR1D1METAP2CHEK1ICMT | |
| SCHEMBL24144070 | 0.81 | HTR6 (0.54) | NR1D1ICMTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | NR1D1 3/4885METAP2 4358/4885AAK1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.